ROIV May 2024 2.500 call
| Previous close | 7.50 |
| Open | N/A |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 7.50 - 7.50 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireRoivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 millionSumitomo Pharma repurchase reduces shares outstanding by 9%In the Phase 2 NEPTUNE study of once-daily oral brepocitinib in non-infectious uveitis (NIU), the 45 mg results represent the best Treatment Failure rates observed to date among active NIU studies measuring this registrational endpoin
PR NewswireRoivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions.
Simply Wall St.Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations
Roivant Sciences ( NASDAQ:ROIV ) Third Quarter 2024 Results Key Financial Results Revenue: US$37.1m (up 118% from 3Q...
